Posts

Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer

on

Biopharma Bites: Boehringer’s 2Q, Keytruda Expansion, and Wegovy’s Market Domination

on

Merck touts Keytruda front-line win in endometrial cancer subtype, marking a PD-1 first

on

Kelun's sac-TMT scores win in first-line PD-L1-negative NSCLC population missing from Merck's KEYTRUDA phase 3 program

on

Gilead's Trodelvy Broad FDA Approval in Front-Line TNBC Fuels TROP2 ADC Market War

on

FDA Approves Merck’s Welireg–Keytruda Combo as Adjuvant Treatment for Kidney Cancer

on

Kelun‑Biotech to Present Two Registrational NSCLC Studies in Oral Session at ASCO 2026: ADC and RET Inhibitor Data in Metastatic NSCLC Patients

on

ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer

on

Roche's Tecentriq, Pfizer/Astellas' Padcev and Merck's Keytruda in Bladder Cancer Battle: Recent Updates

on

Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial

on

Astellas Submits Supplemental New Drug Application in Japan for PADCEV (Enfortumab Vedotin) + Keytruda (Pembrolizumab) for Muscle-Invasive Bladder Cancer

on

Merck's Keytruda Sets New Standard in Platinum-Resistant Ovarian Cancer with First IO Overall Survival Win

on

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

on

ESMO 2025 KEYNOTE-671 Update: Perioperative Pembrolizumab Reinforces NSCLC Standard

on

Merck & Co. Announces Keytruda Achieves First Overall Survival Benefit in Resistant Ovarian Cancer

on

Moderna Unveils Promising mRNA-4359 Cancer Antigen Therapy Data in Melanoma Ahead of ESMO 2025

on

Phase III Study: Perioperative Padcev & Keytruda Combo Significantly Improves Survival in Bladder Cancer

on

Merus Phase 2 Data: Analysts See Strong Survival in Head & Neck Cancer, 'Home Run' Hopes Emerge

on

Merck's Keytruda Achieves Industry-First Success in Preventing Head and Neck Cancer Recurrence: AACR 2025 Highlights

on